Recommend Technology Appraisals

Service Notification Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer

Service Notification Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor (review of TA909)

Service Notification Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over

Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable

Service Notification Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy

Service Notification Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy

Service Notification Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis

Service Notification Guselkumab for previously treated moderately to severely active Crohn's disease

Service Notification Guselkumab for treating moderately to severely active ulcerative colitis

Dapagliflozin for treating chronic kidney disease

Idebenone for treating visual impairment in Lebers hereditary optic neuropathy in people 12 years and over

Relugolixestradiolnorethisterone for treating symptoms of endometriosis (002)

Service Notification Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma

Service Notification Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer

Service Notification 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites 

Service Notification Linzagolix for treating symptoms of endometriosis 

Service Notification Nirmatrelvir plus ritonavir sotrovimab and tocilizumab for treating COVID-19

Service Notification Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

Durvalumab with Etoposide and either Carboplatin or Cisplatin for untreated extensive-stage small-cell lung cancer

Service Notification Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer